Stockscreener 앱 받기
3.38
1.02%
-0.035
시간 외 거래:
3.44
0.06
+1.78%
전일 마감가:
$3.415
열려 있는:
$3.45
하루 거래량:
5,934
Relative Volume:
0.13
시가총액:
$99.52M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-11.98%
1개월 성능:
-8.65%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$3.3501
$3.45
1주일 범위
$3.3501
$3.84
52주 변동 폭
$2.5701
$26.50
Turn Therapeutics Inc Stock (TTRX) Company Profile
명칭
Turn Therapeutics Inc
전화
(818) 564-4011
주소
250 NORTH WESTLAKE BLVD., WESTLAKE VILLAGE
Compare TTRX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TTRX
Turn Therapeutics Inc
|
3.38 | 100.56M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.14 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Turn Therapeutics Inc Stock (TTRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-29 | 개시 | D. Boral Capital | Buy |
Turn Therapeutics Inc 주식(TTRX)의 최신 뉴스
TTRX: Phase II eczema trial for a novel IL-36/IL-31 inhibitor expects key data in Q2 2026 - TradingView
Turn Therapeutics Talks GX-03 Phase II Eczema Data Timeline and Non-Systemic Topical Strategy - Defense World
TTRX: Lead topical for eczema in phase II, with phase III trials planned and strong safety data - TradingView
Technical Analysis of Turn Therapeutics Inc. (NASDAQ:TTRX) - TradingView
Turn Therapeutics Appoints Robert Redfield as Senior Advisor - TipRanks
Turn appoints Dr. Robert Redfield as senior advisor to guide GX-03 regulatory and clinical strategy - TradingView
Former CDC director joins Turn Therapeutics (TTRX) as senior health policy advisor - Stock Titan
Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs - Caledonian Record
How much upside does Compass Therapeutics Inc. haveWall Street Watch & Daily Stock Momentum Reports - mfd.ru
What is the next catalyst for Palvella Therapeutics Inc.July 2025 Spike Watch & Consistent Return Investment Signals - mfd.ru
TTRX Should I Buy - Intellectia AI
Turn Therapeutics Inc.Common Stock (Nasdaq:TTRX) Stock Quote - FinancialContent
Will Ovid Therapeutics Inc. announce a stock splitQuarterly Market Review & Detailed Earnings Play Strategies - mfd.ru
Can Xilio Therapeutics Inc. expand into new marketsDollar Strength & Entry Point Confirmation Signals - mfd.ru
Aug Sentiment: What is the fair value of Candel Therapeutics Inc. stock nowJuly 2025 Reactions & Weekly Top Stock Performers List - mfd.ru
Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences - BioSpace
Turn Therapeutics Highlights GX-03 Progress at Investor Conferences - TipRanks
Turn Therapeutics Inc Announces Presentations at Healthcare Conferences - TradingView
Will Turn Therapeutics Turn The Corner In 2026? - RTTNews
Positive Signs As Multiple Insiders Buy Turn Therapeutics Stock - Yahoo Finance
Analyzing Turn Therapeutics (TTRX) & The Competition - Defense World
TTRX Forecast — Price Prediction for 2026. Should I Buy TTRX? - Intellectia AI
When Will Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Turn A Profit? - Yahoo Finance
Turn Therapeutics Advances GX-03 Eczema Trial, Opening a New Catalyst for Investors - TipRanks
Reviewing Turn Therapeutics (TTRX) and Its Peers - Defense World
Turn Therapeutics' (TTRX) Buy Rating Reiterated at D. Boral Capital - MarketBeat
Turn Therapeutics (TTRX) vs. Its Peers Head to Head Survey - Defense World
Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Turn Therapeutics advances atopic dermatitis trial, expands pipeline - Investing.com Nigeria
Speculative Buy on Turn Therapeutics: Proprietary Platform, Capital-Efficient Growth, and 2026 Milestones as Key Upside Catalysts - TipRanks
Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare Conference - BioSpace
Turn Therapeutics advances atopic dermatitis trial, expands pipeline By Investing.com - Investing.com India
Turn Therapeutics Issues Corporate, Pipeline and Financial Updates - TipRanks
Turn Therapeutics Inc Announces Corporate and Pipeline Updates for 2026 - TradingView — Track All Markets
Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44 - Business Wire
Turn Therapeutics Announces Corporate And Pipeline Updates And 2026 Outlook Ahead Of The 44Th Annual J.P. Morgan Healthcare Conference - TradingView
Financial Review: Turn Therapeutics (TTRX) & Its Peers - Defense World
TTRX Forecast — Price Target — Prediction for 2027 - TradingView — Track All Markets
Turn Therapeutics Reaches US$132m Market Cap Benefiting Insider Stock Buying - Sahm
Will Stoke Therapeutics Inc. stock split again soonVolume Spike & Technical Buy Zone Confirmations - ulpravda.ru
Great week for Turn Therapeutics Inc. (NASDAQ:TTRX) insiders who have 59% stake and they haven’t stopped buying - Yahoo Finance
Turn Therapeutics adds McKinsey veteran to board amid M&A focus By Investing.com - Investing.com Nigeria
Los Angeles Daily NewsTurn Therapeutics Inc.Common Stock (Nasdaq:TTRX) Stock Quote - FinancialContent
Turn Therapeutics appoints Martin Dewhurst to its board of directors - marketscreener.com
Turn Therapeutics Appoints Martin Dewhurst to its Board of Directors - TradingView — Track All Markets
Turn Therapeutics appoints veteran executive to board - TipRanks
Turn Therapeutics adds McKinsey veteran to board amid M&A focus - Investing.com
Turn Therapeutics Inc. Appoints Martin Dewhurst to Board of Directors - TradingView — Track All Markets
Turn Therapeutics (TTRX) Stock Analysis Report | Financials & Insights - Benzinga
Ceapro (OTCMKTS:CRPOF) vs. Turn Therapeutics (NASDAQ:TTRX) Head to Head Review - Defense World
Turn Therapeutics (NASDAQ:TTRX) Upgraded at D Boral Capital - Defense World
Turn Therapeutics Inc (TTRX) 재무 분석
Turn Therapeutics Inc (TTRX)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Turn Therapeutics Inc 주식 (TTRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| GOLDEN ARTHUR F | Director |
Nov 24 '25 |
Buy |
3.44 |
9,868 |
33,946 |
60,602 |
| GOLDEN ARTHUR F | Director |
Nov 21 '25 |
Buy |
2.87 |
20,532 |
58,927 |
50,734 |
| Chaudhary Zuraiz | See Remarks |
Nov 20 '25 |
Buy |
2.61 |
1,450 |
3,784 |
9,000 |
| Chaudhary Zuraiz | See Remarks |
Nov 21 '25 |
Buy |
3.29 |
1,000 |
3,290 |
10,000 |
| Chaudhary Zuraiz | See Remarks |
Nov 17 '25 |
Buy |
3.62 |
2,500 |
9,050 |
7,550 |
| Chesed Abraham | Board Observer |
Oct 23 '25 |
Buy |
4.60 |
14,286 |
65,716 |
1,447,268 |
| Chaudhary Zuraiz | See Remarks |
Oct 23 '25 |
Buy |
4.95 |
5,050 |
24,998 |
5,050 |
| GOLDEN ARTHUR F | Director |
Oct 23 '25 |
Buy |
4.95 |
20,202 |
100,000 |
30,202 |
3.69%
0.71%
자본화:
|
볼륨(24시간):